Ticagrelor is a PO drug which inhibits platelet aggregation. In combination with aspirin it is more effective than clopidogrel + aspirin at reducing the endpoint of MI or death from vascular events.
It will be started by secondary care and continued by cardiologists, so we shouldn’t really have to initiate it.
It will be started in patients who’ve had a STEMI where primary percutaneous coronary intervention (PCI) is considered and also in patients with a NSTEMI who have certain other risk factors.
Generally the side-effects are mainly easy bleeding, but dyspnoea is also an important side-effect, though it is normally just short episodes which are tolerated well.
You can’t use ketoconazole or clarithromycin with it, nor should it be used in moderate to severe hepatic failure.
Latest posts by Louise Hudman (see all)
- Nice | Who should we be testing for cirrhosis? - October 3, 2016
- Nice | Non-alcoholic fatty liver disease NAFLD - August 26, 2016
- Evolocumab and Alirocumab for treating dyslipidaemia - August 25, 2016